Neuroprotection for prevention and treatment of glaucoma in adults

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Sena, Dayse F ^a   Ramchand, K ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIMONIDINE; CALCIUM CHANNEL BLOCKING AGENT; GINKGO BILOBA EXTRACT; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; SCAVENGER;

CLINICAL TRIAL; DRUG MECHANISM; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; NEUROPROTECTION; OPEN ANGLE GLAUCOMA; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; VISUAL ACUITY;

EID: 44949254050     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006539     Document Type: Review

References (34)

1. AGIS 1994 Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology 1994;101(8):1445-55.
2. Anderson 2003 Anderson DR. Collaborative normal tension glaucoma study. Current Opinion in Ophthalmology 2003;14:86-90.
3. Armaly 1980 Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr, Kolker AE, et al.Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Archives of Ophthalmology 1980;98:2163-71.
4. Bathija 1998 Bathija R, Gupta N, Zangwill L, Weinreb RN. Changing definition of glaucoma. Journal of Glaucoma 1998;7:165-9.
5. Bonomi 2002 Bonomi L. Epidemiology of angle-closure glaucoma. Acta Ophthalmologica Scandinavica 2002;236(Suppl):11-3.
6. Brubaker 1996 Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. American Journal of Ophthalmology 1996;121:473-83.
7. Cockburn 1983 Cockburn DM. Does reduction of intraocular pressure (IOP) prevent visual field loss in glaucoma?. American Journal of Optometry and Physiological Optics 1983;60:705-11.
8. Deeks 2006 Deeks JJ, Higgins JPT, Altman DG, editors. Analysing and presenting data. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 8. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
9. Foster 2000 Foster PJ, Wong JS, Wong E, Chen FG, Machin D, Chew PT. Accuracy of clinical estimates of intraocular pressure in Chinese eyes. Ophthalmology 2000;107:1816-21.
10. Glanville 2006 Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
11. Gupta 1997 Gupta N, Weinreb RN. New definitions of glaucoma. Current Opinion in Ophthalmology 1997;8:38-41.
12. Hauser 2006a Hauser MA, Allingham RR, Linkroum K, Wang J, LaRocque-Abramson K, Figueiredo D, et al.Distribution of WDR36 DNA sequence variants in patients with primary open-angle glaucoma. Investigative Ophthalmology & Visual Science 2006;47:2542-6.
13. Hauser 2006b Hauser MA, Sena DF, Flor J, Walter J, Auguste J, Larocque-Abramson K, et al.Distribution of optineurin sequence variations in an ethnically diverse population of low-tension glaucoma patients from the United States. Journal of Glaucoma 2006;15:358-63.
14. Heijl 2002 Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology 2002;120:1268-79.
15. Higgins 2006 Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 6. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
16. Hunter 2005 Hunter DJ. Gene-environment interactions in human diseases. Nature Reviews Genetics 2005;6:287-98.
17. Kamal 1998 Kamal D, Hitchings R. Normal tension glaucoma - a practical approach. British Journal of Ophthalmology 1998;82:835- 40.
18. Levin 1999 Levin LA. Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Survey of Ophthalmology 1999;43 Suppl 1:S98-101.
19. Neacsu 2003 Neacsu A, Oprean C, Curea M, Tuchila G, Trifu M. Neuroprotection with carotenoids in glaucoma. Oftalmologia 2003;59:70-5.
20. Neufeld 1997 Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Archives of Ophthalmology 1997;115:497-503.
21. Neufeld 1998 Neufeld AH. New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. Journal of Glaucoma 1998;7:434-8.
22. Nouri-Mahdavi 2004 Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, et al.Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111(9):1627-35.
23. Osborne 2003 Osborne NN, Chidlow G, Wood J, Casson R. Some current ideas on the pathogenesis and the role of neuroprotection in glaucomatous optic neuropathy. European Journal of Ophthalmology 2003;13 Suppl 3:S19-26.
24. Quigley 1999 Quigley HA. Neuronal death in glaucoma. Progress in Retinal and Eye Research 1999;18:39-57.
25. Quigley 2001 Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Archives of Ophthalmology 2001;119:1819- 26.
26. Quigley 2006 Qugley HA. Number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology 2006;90(3):262- 7.
27. Ramakrishnan 2003 Ramakrishnan R, Nirmalan PK, Krishnadas R, Thulasiraj RD, Tielsch JM, Katz J, et al.Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey. Ophthalmology 2003;110:1484-90.
28. Resnikoff 2004 Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al.Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 2004;82:844- 51.
29. Schwartz 1996 Schwartz M, Belkin M, Yoles E, Solomon A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. Journal of Glaucoma 1996;5:427-32.
30. Schwartz 2000 Schwartz M, Yoles E. Neuroprotection: a new treatment modality for glaucoma?. Current Opinion in Ophthalmology 2000;11:107-11.
31. Shields 1996 Shields M. Classification of the Glaucomas. St. Louis: Mosby, 1996.
32. Tielsch 1991 Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. Journal of the American Medical Association 1991;266:369-74.
33. Vass 2004 Vass C, Findl O, Sycha T, Bauer P, Schmetterer L. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database of Systematic Reviews 2004, Issue 3.Art. No.: CD003167. DOI:10.1002/14651858.CD003167.pub2.
34. Weinreb 1999 Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma?. Archives of Ophthalmology 1998;117:1540-4.